A phase II study of menthol for chemotherapy induced peripheral neuropathy

A phase II study of menthol for chemotherapy induced peripheral neuropathy - A phase II study of menthol for chemotherapy induced peripheral neuropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004913

Enrollment

Registered

2011-01-20

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy induced peripheral neuropathy

Interventions

menthol, twice daily spread to affected areas and skin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Recieving chemotherapy for cacner. 2)symptomatic peripheral neuropathy (grade2,3,4 CTC-AE 4.0). 3)ECOG Performance status 0,1. 4)Able to administration of menthol. 5)Able to write neuropathy check sheat. 6)Life expectancy at least 3months. 7)All patients provided written informed consent before initiation of study-related procedures.

Exclusion criteria

Exclusion criteria: 1)Sever skin disease. 2)Severe symptom due to cacner. 3)Severe toxicity indued by chemotherapy. 4)Other disease which causes peripheral neuropathy. 5)Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
good response rate compliance safety	—

Countries

Japan

Contacts

Public ContactMasato Nakamura

Aizawa Hospital Aizawa comprehensive cancer center

geka-dr7@ai-hosp.or.jp0263-33-8600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026